Promising target for CAR T cells helps cancer trick the immune system
Immunotherapy using modified chimeric antigen receptor (CAR) T cells has greatly improved survival rates for relapsed and recurrent pediatric leukemia and lymphomas, but not brain and solid tumors.
21-Nov-2023 11:05 AM EST
Add to Favorites